THERANEXUS

Theranexus reports €1.5M cash on hand as of 12/12/2024, expecting €4.8M more from Exeltis, Bpifrance, and banking partners, extending cash flow to Q1 2026. CEO highlights industrial partnership with Exeltis as a milestone, aiming for first royalties in 2026.

Patients with juvenile Batten disease treated with Batten-1 (miglustat) for 18 months showed no vision deterioration, with continued treatment indicating possible stabilization of visual acuity. Both FDA and EMA approved Phase 3 trial design, with Theranexus funding a study on a liquid formulation of Batten-1. Phase 1/2 study results suggest Batten-1 may stabilize motor symptoms and vision, supporting its potential as a disease-modifying therapy.

The article contains a PDF document with encoded content, including various symbols, characters, and encoded text, which appears to be a complex and possibly encrypted data stream.